Pathophysiology of complications
Ineffective erythropoiesis drives bone marrow expansion.
Medullary expansion causes characteristic skeletal deformities.
Chronic tissue hypoxia stimulates erythropoietin production.
Erythroid factor erythroferrone promotes excess intestinal iron absorption.
Chronic red blood cell transfusions compound iron loading.
Unbound iron deposits in visceral organs causing systemic hemosiderosis.
Hematological and reticuloendothelial complications
Hypersplenism and splenomegaly
Chronic hemolysis and extramedullary hematopoiesis enlarge spleen.
Progressive hypersplenism causes worsening anemia, leukopenia, and thrombocytopenia.
Reduces survival of autologous and transfused red blood cells.
Management :
Splenectomy indicated if annual packed red blood cell requirement exceeds 200-250 ml/kg/year.
Splenectomy indicated for symptomatic massive splenomegaly or severe cytopenias.
Pre-operative polyvalent pneumococcal, meningococcal, and haemophilus influenzae vaccines required at least 2 weeks prior.
Post-operative daily prophylactic oral penicillin (250 mg twice daily) mandatory.
Alloimmunization
Development of antibodies against transfused red cell antigens.
Incidence reaches 17.6%, primarily involving Kell and Rh groups.
Management :
Perform extended red cell antigen phenotyping at diagnosis prior to initial transfusion.
Administer leukodepleted blood matched for ABO, Cc, Ee, and Kell antigens.
Skeletal complications
Frontal bossing, prominent malar eminences, depressed nasal bridge, maxillary prominence.
Skull radiograph demonstrates classic hair-on-end appearance due to diploic space widening.
Osteopenia and osteoporosis highly prevalent (approximately 60% in adults).
Etiology remains multifactorial: medullary expansion, hypogonadism, nutritional deficits, chelator toxicity.
Management :
Initiate annual bone densitometry screening by age 10.
Maintain pre-transfusion hemoglobin above 9.5 g/dl to suppress marrow expansion.
Administer calcium, vitamin d, and zinc supplementation.
Provide hormone replacement therapy for underlying gonadal insufficiency.
Administer bisphosphonates to inhibit osteoclast-mediated bone resorption.
Iron overload complications
Pathophysiology of Iron Overload
Physiologic mechanism for excess iron excretion absent in humans.
Transfusional iron load: 1 mL pure packed RBCs yields ~1 mg iron.
Increased gastrointestinal iron absorption driven by ineffective erythropoiesis.
Iron deposition sequence: Liver followed by endocrine organs, then heart.
Morbidity: Cardiomyopathy (arrhythmias, heart failure), endocrinopathy (hypothyroidism, diabetes mellitus, hypogonadism, hypoparathyroidism), liver cirrhosis.
Cardiac complications
Myocardial iron deposition causes heart failure and arrhythmias.
Represents primary cause of mortality in thalassemia major.
Diagnosis :
Cardiac T2 star magnetic resonance imaging.
Value less than 10 ms indicates severe iron loading and high cardiac risk.
Management :
Maintain rigorous chelation adherence.
For cardiogenic shock: Initiate continuous intravenous deferoxamine (50-60 mg/kg/day).
Combine with oral deferiprone (75-99 mg/kg/day) for synergistic cardiac iron removal.
Utilize diuretics cautiously to prevent acute renal failure due to high baseline preload.
Endocrine complications
Pituitary and glandular iron toxicity causes multiple endocrinopathies.
Manifests as growth retardation, delayed puberty, hypogonadism, diabetes mellitus, hypothyroidism, and hypoparathyroidism.
Management :
Monitor growth parameters quarterly.
Screen annually for fasting glucose, fructosamine, thyroid function, parathyroid hormone, and sex hormones starting age 10.
Administer exogenous hormone replacement (thyroxine, growth hormone, estrogen, testosterone) as indicated.
Hepatic complications
Iron deposition causes liver fibrosis and eventual cirrhosis.
Liver damage exacerbated by concomitant hepatitis b or c infection.
Management :
Monitor liver iron concentration via magnetic resonance imaging or biopsy.
Adjust chelation to target liver iron concentration 2-5 mg/g dry weight.
Administer hepatitis a and b vaccinations.
Consult gastroenterology for antiviral management if hepatitis c positive.
Monitoring Iron Burden
Serum Ferritin: Assess every 6 months. Target range 500-1500 ng/mL. Initiate chelation if >1000 ng/mL.
Liver Iron Concentration (LIC): Noninvasive MRI (R2/R2*) preferred. Target LIC 2-5 mg Fe/g dry weight (dw). LIC >15 mg/g dw increases cardiac disease/death risk.
Cardiac Iron (T2* MRI): Annual evaluation starting at age 10.
T2* >20 ms: Minimal cardiac iron loading (optimal goal).
T2* 10-19 ms: Mild-to-moderate loading; requires chelation intensification.
T2* <10 ms: Severe loading; high risk of arrhythmia/heart failure; requires aggressive dual therapy.
Chelation Agents
Objective: Bind free extracellular iron, remove intracellular iron, reverse organ dysfunction.
Initiation criteria: >10-20 transfusions, serum ferritin >1000 ng/mL on two occasions, or LIC >5 mg/g dw.
Property Deferasirox (Desirox) Deferiprone (Kelfer) Deferoxamine (Desferal) Administration Oral (dispersible/film-coated/granules) Oral (tablet/solution) Subcutaneous or Intravenous Dosage 20-40 mg/kg/d (dispersible); 14-28 mg/kg/d (film-coated) 50-100 mg/kg/d (divided 2-3 doses) 25-60 mg/kg/d (over 8-24 hours) Frequency Once daily 2-3 times daily 5-7 days/week Excretion Feces (~90%) Urine (~75-90%) Urine (60%), Feces (40%) Cardiac Efficacy Moderate High Moderate Major Toxicity Nephrotoxicity, hepatotoxicity, gastrointestinal bleeding, rash Agranulocytosis (1-2%), neutropenia, arthropathy, elevated transaminases Local reactions, visual/auditory impairment, metaphyseal dysplasia Monitoring Monthly RFT, LFT, Urine R/E Weekly/Monthly CBC with differential Annual visual/auditory exam. Maintain mean daily dose (mg/kg) to ferritin ratio <0.025
Combination Therapy: Indicated for severe iron overload (e.g., elevated cardiac iron). Deferoxamine + Deferiprone or Deferoxamine + Deferasirox combinations utilized.
Vascular and pulmonary complications
Pulmonary hypertension and thrombosis
Characterized by resting pulmonary artery systolic pressure greater than 25 mmhg.
Screen utilizing echocardiography; tricuspid regurgitant jet velocity greater than 2.5 m/s indicates high risk.
Splenectomy significantly exacerbates risk for both pulmonary hypertension and venous thromboembolism.
Management :
Maintain adequate transfusion regimen.
Avoid splenectomy unless strictly indicated.
Consider prophylactic aspirin or anticoagulation for patients with additional thrombotic risk factors.
Other significant complications
Infections
Highest risk follows splenectomy due to encapsulated organisms (streptococcus pneumoniae, haemophilus influenzae, neisseria meningitidis).
Deferoxamine therapy increases susceptibility to yersinia enterocolitica sepsis.
Management :
Educate families to seek immediate evaluation for fever.
In suspected septic shock, immediately hold all chelation therapy.
Administer aggressive fluid resuscitation and broad-spectrum intravenous antibiotics (third-generation cephalosporin plus aminoglycoside).
Cholelithiasis
Chronic hemolysis increases bilirubin turnover causing pigmented gallstones.
Management :
Perform abdominal ultrasound for symptomatic patients.
Laparoscopic cholecystectomy indicated for symptomatic disease.
Leg ulcers
Occur over malleoli due to increased venous pressure from expanded bone marrow volume.
Management :
Leg elevation, meticulous wound hygiene, elastic compression stockings.
Oral zinc sulfate supplementation.
Temporary intensive transfusion therapy for 3-6 months for refractory cases.
🌱 This is a Digital Garden. Notes are always growing and changing.
These notes are intended for educational purposes only and reflect my personal understanding of the subject. Please cross-reference with standard textbooks and current clinical guidelines.
Authored by Dr. Rubanbalaji 2026